OncoMatch/Clinical Trials/NCT05156060
Gabapentin & Ketamine for Prevention/Treatment of Acute/Chronic Pain in Locally Advanced Head and Neck Cancer
Is NCT05156060 recruiting? Yes, currently enrolling (May 2026). This Phase 1/2 trial studies multiple treatments including Gabapentin and Ketamine for head and neck cancer.
Treatment: Gabapentin · Ketamine — This is a study to establish a safe and feasible dose for prophylactic use of a combination of gabapentin and ketamine in head and neck cancer patients undergoing chemoradiation.
Check if I qualifyExtracted eligibility criteria
Cancer type
Head and Neck Squamous Cell Carcinoma
Disease stage
Required: Stage T3N0M0, T4N0M0, T1N1M0, T2N1M0, T3N1M0, T4N1M0, T1N2M0, T2N2M0, T3N2M0, T4N2M0, T1N3M0, T2N3M0, T3N3M0, T4N3M0 (TNM)
Locally advanced non-metastatic disease (T3N0M0, T4N0M0, T1-4N1-3M0)
Performance status
ECOG 0–2(Ambulatory, capable of self-care)
Lab requirements
Kidney function
glomerular filtration rate <30 mL/min/1.73 m2 [excluded]
Glomerular filtration rate <30 mL/min/1.73 m2
Structured fields extracted by AI. May contain errors — verify against the official protocol.
US trial sites
- Vanderbilt-Ingram Cancer Center · Nashville, Tennessee
Showing up to 5 US sites. See all sites on ClinicalTrials.gov →
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify